Aphria (TSE:APH) received a C$31.00 price objective from equities research analysts at Bryan, Garnier & Co in a research report issued to clients and investors on Sunday, October 14th. The firm currently has a “buy” rating on the stock. Bryan, Garnier & Co’s price target points to a potential upside of 110.60% from the stock’s current price.
Separately, Canaccord Genuity lowered their price objective on shares of Aphria from C$25.50 to C$24.50 and set a “c$11.25” rating on the stock in a research report on Wednesday, July 18th.
TSE APH opened at C$14.72 on Friday. Aphria has a 1 year low of C$6.72 and a 1 year high of C$24.75.
Aphria (TSE:APH) last posted its quarterly earnings data on Wednesday, August 1st. The company reported C($0.04) earnings per share for the quarter, missing the consensus estimate of C($0.02) by C($0.02). Aphria had a return on equity of 7.63% and a net margin of 75.91%. The firm had revenue of C$12.03 million for the quarter, compared to analysts’ expectations of C$11.22 million.
About Aphria
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Posts
